Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
personal-finance
Can you achieve global diversification with multinational companies?
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,624.90 | 6.60 | -0.08% |
CAC 40 | 7,788.10 | 38.69 | -0.49% |
DAX 40 | 24,038.19 | 188.30 | -0.78% |
Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
FTSE 100 | 8,726.01 | 52.04 | -0.59% |
HKSE | 23,258.31 | 123.68 | -0.53% |
NASDAQ | 19,100.94 | 98.22 | -0.51% |
Nikkei 225 | 37,722.40 | 1.71 | -0.00% |
NZX 50 Index | 12,279.91 | 82.35 | -0.67% |
S&P 500 | 5,888.55 | 32.99 | -0.56% |
S&P/ASX 200 | 8,396.90 | 10.70 | -0.13% |
SSE Composite Index | 3,339.93 | 0.76 | -0.02% |